Literature DB >> 15094276

Pulmonary embolism.

Samuel Z Goldhaber1.   

Abstract

Pulmonary embolism (PE) is a common illness that can cause death and disability. It is difficult to detect because patients present with a wide array of symptoms and signs. The clinical setting can raise suspicion, and certain inherited and acquired risk factors predispose susceptible individuals. D-dimer concentration in blood is the best laboratory screening test, and chest CT has become the most widespread imaging test. Treatment requires rapid and accurate risk stratification before haemodynamic decompensation and the development of cardiogenic shock. Anticoagulation is the foundation of therapy. Right-ventricular dysfunction on echocardiography and higher than normal concentrations of troponin identify high-risk patients who might need escalation of therapy with thrombolysis or embolectomy even if the blood pressure is normal on presentation. When patients are admitted to medical wards or when patients undergo surgery, their physicians should prescribe prophylactic measures to prevent PE. After hospital discharge, prophylaxis should continue for about a month for patients at high risk of thromboembolism.

Entities:  

Mesh:

Year:  2004        PMID: 15094276     DOI: 10.1016/S0140-6736(04)16004-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  54 in total

1.  Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis.

Authors:  Muhammad Ali; Ashwin N Ananthakrishnan; Emily L McGinley; Kia Saeian
Journal:  Dig Dis Sci       Date:  2011-01-30       Impact factor: 3.199

2.  Cardiac troponins.

Authors:  S Sharma; P G Jackson; J Makan
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  [Computer-assisted diagnostic procedure for multislice computed tomography for assessment of the pulmonary arterial circulation. Clinical relevance].

Authors:  A Malich; D Hentrich; A Hansch; J Böttcher; U Teichgräber
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

Review 4.  [MRI of pulmonary embolism].

Authors:  C Fink; S Thieme; S Ley; D Clevert; M F Reiser; H-U Kauczor; S O Schoenberg
Journal:  Radiologe       Date:  2007-08       Impact factor: 0.635

5.  Optimized image reconstruction for detection of deep venous thrombosis at multidetector-row CT venography.

Authors:  Marco Das; Georg Mühlenbruch; Andreas Horst Mahnken; Claudia Weiss; U Joseph Schoepf; Christianne Leidecker; Rolf W Günther; Joachim Ernst Wildberger
Journal:  Eur Radiol       Date:  2005-08-02       Impact factor: 5.315

Review 6.  [Ventilation-perfusion scintigraphy for the diagnosis of pulmonary embolism].

Authors:  T D Pöppel; B J Krause
Journal:  Radiologe       Date:  2007-08       Impact factor: 0.635

7.  Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin.

Authors:  Hilary M Pearce; Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

8.  Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score.

Authors:  Vittorio Palmieri; Giovanni Gallotta; Domenico Rendina; Silvana De Bonis; Vittorio Russo; Alfredo Postiglione; Stefania Martino; Matteo Nicola Dario Di Minno; Aldo Celentano
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

Review 9.  Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT.

Authors:  John H Reid; Emmanuel E Coche; Tomio Inoue; Edmund E Kim; Maurizio Dondi; Naoyuki Watanabe; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-27       Impact factor: 9.236

10.  The autopsy and diagnosis of pulmonary thrombo-embolism.

Authors:  Milton J Micallef
Journal:  Forensic Sci Med Pathol       Date:  2018-02-05       Impact factor: 2.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.